The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global mammalian polyclonal IgG antibody market size reached US$ 984.81 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,351.73 Million by 2027, exhibiting a growth rate (CAGR) of 5.25% during 2022-2027.
Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations. Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.
The increasing prevalence of various chronic disorders, including cancer and autoimmune ailments, and the rising need for antibodies for multiple immunoassay tests and therapeutic and analytical applications in research settings are primarily driving the market growth. In line with this, significant investments in biotechnology and pharmaceutical companies by governments to formulate effective novel vaccinations and injectables through advanced technologies are acting as another growth-inducing factor. Additionally, the ongoing innovation of creative mammalian antibodies by biopharma organizations for quality control (QC) is contributing to the market growth. Moreover, the escalating biomarkers approval and their extensive usage by clinicians for accurate and rapid diagnosis of B-cell lymphoma and leukemia are supporting the market growth. Apart from this, significant enhancements in the healthcare infrastructure and research and development (R&D) activities to enhance antibody efficacy are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global mammalian polyclonal IgG antibody market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, product, application and end use.
Breakup by Type:
Breakup by Product:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbiotec Inc., Abcam plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Creative Diagnostics, Elabscience Biotechnology Inc., Geno Technology Inc., Merck KGaA, Proteintech Group Inc., STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Product, Application, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbiotec Inc., Abcam plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Creative Diagnostics, Elabscience Biotechnology Inc., Geno Technology Inc., Merck KGaA, Proteintech Group Inc., STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at